NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Free Report) – Equities research analysts at HC Wainwright lowered their Q4 2027 earnings per share (EPS) estimates for shares of NRx Pharmaceuticals in a research note issued to investors on Thursday, May 28th. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.36 per share for the quarter, down from their previous forecast of $0.48. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2030 earnings at $5.76 EPS.
Several other analysts have also recently issued reports on NRXP. Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. BTIG Research reaffirmed a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, March 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Friday, May 8th. D. Boral Capital reissued a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. Finally, Ascendiant Capital Markets boosted their target price on NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.25.
NRx Pharmaceuticals Price Performance
Shares of NRXP opened at $4.44 on Friday. The stock has a market capitalization of $160.86 million, a price-to-earnings ratio of -4.07 and a beta of 2.02. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $4.55. The business’s 50 day simple moving average is $2.73 and its 200-day simple moving average is $2.36.
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $19.43 million.
Hedge Funds Weigh In On NRx Pharmaceuticals
Several hedge funds have recently bought and sold shares of NRXP. Anson Funds Management LP grew its position in NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares during the last quarter. Commonwealth Equity Services LLC bought a new position in NRx Pharmaceuticals in the 4th quarter valued at $994,000. Bleakley Financial Group LLC bought a new position in NRx Pharmaceuticals in the 4th quarter valued at $318,000. AdvisorShares Investments LLC grew its position in NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after acquiring an additional 92,463 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares during the last quarter. Institutional investors own 4.27% of the company’s stock.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.
Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.
Further Reading
- Five stocks we like better than NRx Pharmaceuticals
- Wall Street Is Starting to Talk About Tesla’s Endgame
- Meta’s Manus Mess: Why China Blocked the Deal and What It Means
- China Deal Ignites Boeing’s Financial Afterburners
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
